This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs and assumptions in light of information currently available to management. Accordingly, the Company's actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in the Company's operations and business environment, including, among other factors, those described in documents filed by the Company with the Securities and Exchange Commission, specifically its Form 10-Ks and 10-Qs. The Company does not assume any obligation to update, amend or clarify such statements to reflect new events, information or circumstances after the date of this presentation.
During the course of this presentation, certain non-GAAP financial information will be presented. Additional information is available on the Company's website at www.aptar.com on the Investor's page (click on Events & Presentations for a Reconciliation of non-GAAP Financial Measures).
Adjusted EBITDA and EPS exclude the impact of restructuring initiatives, acquisition related costs, and net unrealized investment gains and losses related to observable market price changes on equity securities. Prior year Adjusted EPS includes foreign currency effects that are approximations of the adjustment necessary to state the prior year earnings per share using current period foreign currency exchange rates.
2
Q2 2022 Financial Highlights
+4%
Reported Sales Growth
+15%
Net Income Growth
+10%
Core Sales Growth*
+8%
Adjusted EBITDA Growth
Highlights:
Increased volumes and price initiatives drove strong second quarter top line growth across each reporting segment
Areas of our business that were negatively impacted by the pandemic, such as our prescription drug, beauty and beverage solutions, are recovering
Deployed over $3 billion since 2017, balanced across
investing in our business,
making acquisitions and
dividends and share repurchases
1H2022:
Capital expenditures of approximately $150 million, the majority of which were in our Pharma segment, including plant capacity expansions in the US, France and China
Returned over $100 million to shareholders through dividends and share repurchases
On track for our 29th consecutive year of increased annual dividend payments and
have repurchased shares every year since 1999, except for 2020
4
Global Sustainability Reporting
Aptar's 2021 Corporate Sustainability Report was released on June 22nd
https://www.aptar.com/esg/reporting-center/
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
AptarGroup Inc. published this content on 28 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2022 21:32:29 UTC.
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. The Company operates through three segments: Aptar Pharma, Aptar Beauty and Aptar Closures. Aptar Pharma segment supplies nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and healthcare markets worldwide and supplies elastomer for injectable primary packaging components worldwide. The segment also provides services designed to accelerate and de-risk the development and regulatory approvals of drugs using drug delivery devices. The Aptar Beauty segment sells a variety of pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care and home care markets. Aptar Closures segment primarily sells dispensing closures.
APTARGROUP, INC. 
